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Comprehensive genome-wide DNA methylation studies in neuroblastoma (NB), a childhood tumor that
originates from precursor cells of the sympathetic nervous system, are scarce. Recently, we proﬁled the
DNA methylome of 102 well-annotated primary NB tumors by methyl-CpG-binding domain (MBD)
sequencing, in order to identify prognostic biomarker candidates. In this data descriptor, we give details on
how this data set was generated and which bioinformatics analyses were applied during data processing.
Through a series of technical validations, we illustrate that the data are of high quality and that the
sequenced fragments represent methylated genomic regions. Furthermore, genes previously described to
be methylated in NB are conﬁrmed. As such, these MBD sequencing data are a valuable resource to further
study the association of NB risk factors with the NB methylome, and offer the opportunity to integrate
methylome data with other -omic data sets on the same tumor samples such as gene copy number and
gene expression, also publically available.
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Background & Summary
Neuroblastoma (NB), a neuro-ectodermal tumor that originates from precursor cells of the sympathetic
nervous system, represents the most common extra-cranial solid tumor of early childhood and is
considered a heterogeneous disease driven by genetic aberrations, as during the past decades mainly
genetic factors have been described to inﬂuence the pathogenesis and disease course (including MYCN
ampliﬁcation, ALK ampliﬁcation and mutation, hyperdiploidy, and gains and losses of speciﬁc
chromosome arms (1p, 3p, 11q and 17q))1. Also, recent comprehensive whole-genome sequencing
studies of primary NB tumors pinpointed chromothripsis and defects in neuritogenesis genes as
important tumor-driving events in a subset of NB2, and indicated that MYCN, TERT and ATRX
alterations deﬁne major subgroups of high-risk NB3,4. However, also epigenetic mechanisms, such as
DNA methylation alterations, seem to contribute to the NB biology and clinical behaviour.
As reviewed in Decock et al.5, multiple DNA methylation alterations have been described in NB, but
given the rare occurrence of the disease, the number of comprehensive genome-wide DNA methylation
studies analyzing primary tumor samples is limited. Hence, most studies initially make use of NB cell
lines and only validate the most obvious methylation alterations in primary NB tumors. For example,
a frequently applied methodology to NB cell lines is assessment of gene expression reactivation upon
5’-aza-2’-deoxycytidine (DAC) treatment, a cytosine analogue that cannot be methylated, leading to
progressive DNA demethylation upon cell division. However, major drawbacks of these studies are that
their discovery phases fall short in covering the NB heterogeneity, as NB cell lines are considered models
for aggressive high-risk tumors, and that DNA methylation detection is indirectly assessed, as the
inﬂuence of the demethylating effect is measured at the transcriptional level6–8. To accommodate this, the
Illumina 27 and 450 K methylation arrays, directly interrogating the status of approximately 27,000 and
485,000 methylation sites, respectively, recently were applied to primary NB tumors6,9–12. Yet, also this
technology has important limitations: the design of the arrays is heavily biased to interrogation of CpG
sites previously described in literature and covers less than 2% of all CpG sites in the human genome13.
Therefore, we generated a data set comprising of 102 primary NB tumors in which DNA methylation
is assessed by massively parallel sequencing of methylation enriched DNA fragments. The applied
method is based on the use of MeCP2, a member of the methyl-CpG-binding domain (MBD) protein
family which speciﬁcally binds to methylated cytosines and enables precipitation of methylated DNA
fragments. This data set is unique in the NB research ﬁeld, as it is the ﬁrst sample cohort in which the full
tumor heterogeneity is being assessed by genome-wide methylation analysis using next-generation
sequencing (NGS); it was originally collected for the identiﬁcation of prognostic biomarker candidates.
Selected candidates were validated in independent cohorts using methylation-speciﬁc PCR and we
showed that MBD sequencing allowed selection of valuable markers which would not have been
identiﬁed using the Illumina methylation arrays14.
Here, we provide a detailed description of the methodological approach and bioinformatics analyses,
as well as easy access to the (analyzed) MBD sequencing data and analysis tools, allowing other
researchers (inexperienced with MBD sequencing) to reuse it. Importantly, the analyzed samples are well
annotated; besides overall and event-free survival data, also following NB characteristics are available: age
of the patient at diagnosis, tumor stage according to the International Neuroblastoma Staging System
(INSS)15 and MYCN ampliﬁcation status. As such, these data offer the opportunity to further explore the
association of these risk factors with the NB methylome. Furthermore, integration of methylome data
with other -omic data sets should be examined in order to fully map the NB biology on a genome-wide
level. The present MBD sequencing data greatly facilitate these integration analyses, considering that for
part of the proﬁled samples matching expression and array comparative genomic hybridization (aCGH)
data are available16–18 (see Methods for details).
In summary, this data descriptor outlines details on the generation and analysis of MBD sequencing
data of 102 primary NB tumors (Fig. 1). As NB is a rare disease and comprehensive DNA methylation
studies scarce, these MBD sequencing data are very valuable and permit further unravelling the role of
DNA methylation in the NB biology.
Methods
DNA sample collection
Two independent cohorts of 42 and 60 primary tumor DNA samples, respectively annotated as MBD
cohort I and II, were sequenced. Samples of fresh frozen tumors were collected at the Ghent University
Hospital (n= 49; Ghent, Belgium), the Hospital Clínico Universitario (n= 42; Valencia, Spain), the
University Children’s Hospital Essen (n= 8; Essen, Germany) and the Our Lady’s Children’s Hospital
Dublin (n= 3; Dublin, Ireland), according to previously published criteria7,14, and stage 4S tumors were
also included. Detailed clinical characteristics of the patients are given in Table 1 (available online only).
For samples 809 and 912, DNA was extracted from different parts of the same primary tumor. Informed
consent was obtained from each patient’s guardian and the study was approved by the ethical committee
of the Ghent University Hospital (approval number B67020109912). Matching expression data16,17 of 38
tumors are available through the NCBI Gene Expression Omnibus (GEO) database (GSE21713 and
GSE32664; sample IDs in Table 1 (available online only)). Matching aCGH data18 of 38 tumors are
available through ViVar19 (https://www.cmgg.be/vivar/; login: review, password: review, project: Kumps
et al. 2013; sample IDs in Table 1 (available online only)).
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Methyl-CpG-binding domain (MBD) sequencing
DNA fragmentation. For each sample, between 400 to 1000 ng DNA was sheared to obtain DNA
fragments with an average length of 200 bp. The DNA was loaded in 120 μl TE buffer (1:5), transferred to
a Snap Cap microTUBE (Covaris) and exposed to Covaris S2 Adaptive Focused Acoustics. Fragment
distribution and concentration was determined on a High Sensitivity DNA chip (Agilent Technologies).
Methylated DNA capturing. Subsequently, capturing of methylated DNA fragments was done
according to the MethylCap kit protocol of Diagenode using 200–500 ng DNA. Elution of the captured
fraction was performed in 150 μl High Elution Buffer and DNA was puriﬁed using the MinElute PCR
puriﬁcation kit (Qiagen). For MBD cohort II, also input samples (10%) were prepared.
Library preparation. As MBD cohort I and II were proﬁled in a different time frame and NGS
methodologies evolve at rapid pace, a different library preparation protocol and sequencing technology
was applied to each of them. For MBD cohort I, DNA library preparation was performed using the
NEBNext DNA Library Prep Master Mix Set for Illumina (New England Biolabs) in combination with
the Multiplexing Sample Preparation Oligonucleotide Kit (Illumina) for paired-end adapter ligation. Size
selection of the library is done on a 2% agarose gel (Bio-Rad). Fragments between 250 and 350 bp were
excised and puriﬁed using a Qiagen Gel Extraction Kit. For MBD cohort II, library preparation was
automated on an Apollo 324 Next Generation Sequencing Library Preparation System (IntegenX),
making use of the PrepX ILM DNA Library Kit (IntegenX). For paired-end adapter ligation the
Multiplexing Sample Preparation Oligonucleotide Kit was used. Size selection was done with 1X AMPure
XP beads (Agencourt) and PEG-Bead Solution.
Library ampliﬁcation. PCR library ampliﬁcation with appropriate Index Primers for each sample was
performed using the Multiplexing Sample Preparation Oligonucleotide Kit and following PCR
conditions: 30 s at 98 °C, 21 ampliﬁcation cycles (10 s at 98 °C, 30 s at 65 °C and 30 s at 72 °C), 5 min
at 72 °C, and held at 4 °C. PCR product puriﬁcation was done using the High Pure PCR Puriﬁcation Kit
(Roche). QC was performed on a DNA 1000 chip (Agilent) and concentration was determined by qPCR
according to the qPCR Quantiﬁcation Protocol Guide of Illumina. Samples were pooled and proﬁled on
Figure 1. The MBD sequencing data of 102 primary neuroblastoma tumors are processed using different
analysis tools. Depicted are the available MBD sequencing data sets and downstream data processing and
technical validation steps. These steps are represented as arrows and circles, respectively. For each step, the
applied tool or analysis is indicated. For the technical validation steps, also the corresponding data descriptor
ﬁgures and tables are indicated. DMA, differential methylation analysis; IGV, Integrative Genomics Viewer;
PE, paired-end; RPKM, reads per kilobase CpG island per million.
www.nature.com/sdata/
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an Illumina GAIIx (PE 2 × 45 bp) for MBD cohort I and on an Illumina HiSeq2000 (PE 2 × 51 bp) for
MBD cohort II.
Data processing and analysis
Sequencing data. All crucial steps in the processing and analysis of the MBD sequencing data are
summarized in Fig. 1. Raw sequencing data were demultiplexed and converted to FASTQ ﬁles (with
sequencing reads and quality scores). Quality control on the raw data was performed by FASTQC
(version 0.9.2; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
Read mapping. Next, the sequencing reads were mapped/aligned to the human reference genome
(hg19), using the Bowtie2 (ref. 20) mapper (version 2.0.0 beta7) and FASTQ ﬁles as input. For each
sample, two paired FASTQ ﬁles are available (as we performed paired-end sequencing), in which the data
lines correspond to each other. To improve the mapping quality, reads were only taken into account if the
sequences in both ﬁles could be mapped to the reference genome (maximum 500 bp between both paired
ends). Also sequencing quality scores were used in the mapping process. The BAM format was used as
output ﬁle type. PCR duplicates were marked with Picard (version 1.79; http://broadinstitute.github.io/
picard/) and the BAM ﬁles were sorted and indexed using SAMtools21 (version 0.1.18) and index
commands. These ﬁles have been deposited as raw data ﬁles in the NCBI Gene Expression Omnibus
(GEO) database (Data Citation 1 for MBD cohort I; Data Citation 2 and Data Citation 3 for MBD cohort
II). FASTQ records can be extracted from the sequence alignments in the BAM ﬁles using the BEDTools
bamtofastq conversion utility22. Starting from the SRA ﬁles, the NCBI SRA Toolkit (fastq-dump) can be
used to generate the FASTQ ﬁles. Mapping quality was evaluated using SAMStat23 (version 1.08) and
BamUtil (version 1.0.2; http://genome.sph.umich.edu/wiki/BamUtil). Technical validation of MBD
enrichment is performed by fragment CpG plot analysis24 and by plotting the densities of the median
numbers of mapped reads per kilobase per million (RPKM25) in all CpG islands (n= 28,691) across the
different subcohorts.
Peak calling. The process of converting mapped sequencing reads to coverage vectors and the detection
of enriched regions (peaks) is referred to as peak detection or peak calling. Here, peak calling was done
using the MACS26 software tool (version 1.4.0 beta) and BAM ﬁles as input. BED ﬁles were generated
(Data Citation 1 for MBD cohort I; Data Citation 2 and Data Citation 3 for MBD cohort II), indicating
the location and score (linked to the P-value) of the identiﬁed peaks.
Visualization. MACS is also used to output WIG ﬁles (Data Citation 1 for MBD cohort I; Data Citation
2 and Data Citation 3 for MBD cohort II), which are transformed to a binary format (TDF ﬁle;
Data Citation 1 for MBD cohort I; Data Citation 2 and Data Citation 3 for MBD cohort II) by igvtools
(https://www.broadinstitute.org/igv/igvtools) for visualization in the Integrative Genomics Viewer
(IGV)27. An example IGV XML-session ﬁle for MBD cohort II and instructions on how to make use
of this ﬁle are included in the GitHub repository (see Code availability).
Differential methylation analyses. Differential methylation analyses between sample groups are
described in detail in Decock et al.14. Brieﬂy, for each subcohort, two count data sets were constructed, in
which for each sample the numbers of mapped reads in the promoter region of the different Ensembl
Transcripts or 5 kb genomic windows are indicated. Here, we provide access to these count data sets
(Supplementary Tables 3–8), which can directly be used for differential methylation analyses in
DESeq14,28.
Code availability. All tools and code that are necessary to generate the described ﬁle types are provided
in a Docker container (Docker Hub; https://hub.docker.com/r/mateongenaert/mbdtoolbox/). More
advanced analysis scripts can be found in the GitHub repository (https://github.com/mateongenaert/
MBDToolBox).
Statistic MBD cohort I—enriched samples MBD cohort II—enriched samples MBD cohort II—input samples
range mean median range mean median range mean median
total read number (e6) 4.65–18.20 13.38 14.17 29.74–66.59 45.09 44.41 20.86–59.51 36.00 33.19
duplicate reads (%) 0.70–72.00 6.46 3.39 2.55–79.69 31.04 19.89 2.24–10.47 4.17 3.68
properly paired reads (%) 48.29–94.51 85.64 89.29 86.86–97.57 95.33 95.72 94.78–97.55 96.50 96.59
Table 2. Using BamUtil, basic sequencing statistics of MBD cohort I and II are computed. Total read
number: the total number of reads in the two paired FASTQ ﬁles of a sample; duplicate reads as a percentage of
the total read number; properly paired reads as a percentage of the total read number.
www.nature.com/sdata/
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Data Records
An overview of the sample annotation and data outputs is given in Table 1 (available online only). The
outputs of each step in the data processing (read mapping: BAM ﬁles, peak calling: BED ﬁles, and
visualization: WIG and TDF ﬁles) have been deposited in the GEO database. For MBD cohort I, the
accession number is GSE69224 (Data Citation 1), for MBD cohort II, GSE69243 (Data Citation 2) and
Figure 2. The per base sequence quality scores indicate that the raw sequencing data are of good quality.
Shown are the distributions of the median per base quality score (determined by FASTQC) of the enriched
samples of MBD cohort I (a), and of the enriched (b) and input (c) samples of MBD cohort II. In the boxplots,
the lower and upper hinge of the boxes represents the 25th and 75th percentile, respectively. The whiskers
extend to the lowest and highest value that is within 1.5 times the interquartile range. Data beyond the end of
the whiskers are outliers and plotted as dots.
www.nature.com/sdata/
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GSE69268 (Data Citation 3). In GEO, these data sets were submitted as SubSeries of the SuperSeries
GSE69279 (Data Citation 4). We also provide a Docker container, made available through Docker Hub,
that embeds all necessary tools to generate the data ﬁles and illustrates the analysis pipeline. More
advanced analysis scripts are given in the GitHub repository (see Code availability).
Technical Validation
Validation of raw and mapped sequencing data
The total read number and percentage of duplicate and properly paired reads in each sample are given in
Supplementary Table 1, and a summary of these sequencing statistics across the different sample cohorts
can be found in Table 2.
To ensure raw data quality, FASTQC analyses were performed to determine the per base sequence
quality which reﬂects the probability that a base has been called incorrectly29. Quality scores between 41
and 28, 28 and 20, and below 20 are considered base calls of very good quality, calls of reasonable quality
and calls of poor quality, respectively. In order to obtain a general overview of the range of quality values
Figure 3. The mapping quality scores illustrate high mapping accuracy. Shown are the distributions of the
percentages of mapped reads across the different mapping quality ranges, as determined by SAMStat ((a)
enriched samples of MBD cohort I, (b) enriched samples of MBD cohort II and (c) input samples of MBD
cohort II). In the boxplots, the lower and upper hinge of the boxes represents the 25th and 75th percentile,
respectively. The whiskers extend to the lowest and highest value that is within 1.5 times the interquartile range.
Data beyond the end of the whiskers are outliers and plotted as dots.
www.nature.com/sdata/
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across all bases at each position, the median quality score for each position in each FASTQ ﬁle was
determined. Fig. 2 shows the distribution of these median per base quality scores across the different
sample cohorts. In general, the quality scores of both MBD cohort I and II are of reasonable to very good
quality. Given the different sequencing technologies that were used for MBD cohort I (Illumina GAIIx)
and II (Illumina HiSeq2000), it is expected that the read quality of MBD cohort II is higher than that of
MBD cohort I. The steadily increase and subsequent decrease in quality along the read is also expected for
Illumina-based experiments29,30.
Mapping quality is ensured by analyzing the mapping quality scores of the alignments in each sample
(Supplementary Table 2). In Fig. 3, the distributions of the percentages of mapped reads across the
different mapping quality ranges are shown. For all subcohorts, the reads are clearly mapped with high
accuracy, as almost for every sample, more than half of the mapped reads has a MAPQ≥ 30 (ref. 23).
Validation of MBD-based enrichment
Over the past years several companies developed commercial kits for MBD-based capturing of
methylated fragments. Although all of them claim to be of high quality, differences in performance exist.
Careful kit selection is thus of utmost importance24. Here, sheared tumor DNA was enriched towards
methylated fragments using the MethylCap kit of Diagenode, that makes use of the methylCap protein,
consisting of the MBD of human MeCP2 fused with gluthatione-S-transferase (GST) containing an
MBD cohort I - enriched samples
MBD cohort II - enriched samples
MBD cohort II - input samples
1
2
3
0
86420
log2(RPKM+1)
de
ns
ity
Figure 5. CpG island RPKM values conﬁrm enrichment towards methylated DNA fragments upon MBD
capture. Shown are the densities of the median RPKM values per subcohort. RPKM: reads per kilobase CpG
island per million.
Figure 4. Fragment CpG plots demonstrate that the MBD-enriched samples have a high fraction of CpG dense
sequencing fragments. Shown are the fractions of mapped MBD sequencing fragments with different CpG
counts. Per cohort, 100,000 randomly selected fragments of each sample were used to construct the plots.
www.nature.com/sdata/
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Figure 6. Visualization of the MBD sequencing data in IGV conﬁrms methylation of the PCDHB gene cluster.
In (a) the data of MBD cohort I is shown, in (b) the data of MBD cohort II. The upper panels show the genes in
the cluster, the location of CpG islands and the GC percentage. In the lower panels, sequence coverage of 6
high-risk patient samples is shown (peak pattern), as well as the location of identiﬁed peaks (horizontal bars).
www.nature.com/sdata/
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N-terminal His6-tag. A previous evaluation assessed the quality of this kit for combination with NGS by
comparison with four other commercially available kits24. This study also compared the MBD sequencing
data with reduced representation bisulﬁte sequencing (RRBS) and Illumina 27 K methylation array data
of the same samples. Together, these analyses showed that the MethylCap kit outperforms the others, due
to a consistent combination of high yield, sensitivity and speciﬁcity24. In order to demonstrate that the
samples of MBD cohort I and II were enriched for methylated DNA fragments after MBD-based
capturing, we made use of the fragment CpG plot24. As this plot depicts the CpG content of the mapped
fragments and the MethylCap kit theoretically only captures methylated cytosines in a CpG dinucleotide
context, the fragment CpG plot can be used to evaluate the MBD-based enrichment. An overview of the
CpG content of the mapped fragments per sample cohort is depicted in Fig. 4. This fragment CpG plot
clearly illustrates that the MBD-enriched samples of MBD cohort I and II have a high fraction of CpG
dense fragments, while the input (non-MBD-enriched) samples of MBD cohort II are not enriched in
CpG content. Additionally, using the number of mapped reads per kilobase CpG island per million
(RPKM) values25, the methylation level of each CpG island across the different subcohorts was
determined. The density plot in Fig. 5 indicates that the MBD-enriched samples have a higher fraction of
CpG islands with an RPKM>1 compared to the input samples of MBD cohort II. Based on these analyses,
it can be concluded that the MBD-based capture successfully led to the enrichment of methylated DNA
fragments.
Validation of methylated genes in neuroblastoma
Finally, TDF and BED ﬁles, containing sequence coverage and peak locations respectively, were loaded
into IGV to visually inspect genes previously described to be methylated in NB. As an example, the MBD
sequencing data of the PCDHB gene cluster is shown in Fig. 6. This gene cluster is frequently methylated
in NB5,31, which is conﬁrmed by the MBD sequencing data of both MBD cohort I and II. Additionally,
78 regions identiﬁed in the MBD sequencing data as being methylated, were validated in two independent
patient cohorts using methylation-speciﬁc PCR (MSP)14. These data conﬁrm the validity of MBD
sequencing in identifying methylated regions in NB.
Usage Notes
The MBD sequencing data can be downloaded from the GEO database via accession numbers GSE69224
(for MBD cohort I; Data Citation 1), GSE69243 and GSE69268 (for MBD cohort II; Data Citation 2 and
Data Citation 3; SuperSeries GSE69279 (Data Citation 4)). The unique GEO sample accession IDs and
clinical annotation can be found in Table 1 (available online only). This table also contains the accession
IDs of the matching expression and aCGH data, which allows easy data access and facilitates integration
analyses.
All output ﬁles from the different steps in the MBD sequencing data processing are provided through
GEO. Analysis tools and scripts have been embedded in a Docker container, to deliver an environment
that runs on any supported host platform (Windows, MAC, Linux). This Docker container, and all
instructions on how it is made and how analyses can be run on the data, are made available through
Docker Hub and GitHub (see Code availability). This allows researchers to try out the analysis pipeline
that was used to generate the publically available data, without the need of additional infrastructure or
software versions. The Docker container guarantees that the provided commands work and allows
researchers to start exploring the data at the level they are experienced with.
Alternative processing tools can be tested for read mapping (e.g., BWA32) or identiﬁcation of enriched
regions (e.g., PeakRanger33 or BALM34), or absolute methylation scores can be calculated (MEDIPS35; see
Code availability). Researchers inexperienced with MBD sequencing can easily visualize their genes of
interest by downloading the BED and TDF ﬁles (see Code availability). Downstream differential
methylation analyses can be done with DESeq28 (as described in Decock et al.14) using count data sets
provided in Supplementary Tables 3–8, or other software can be used, such as DiffBind36 and edgeR37.
Differences in absolute methylation scores can be used for RankProd38 analyses.
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